ISSN:
1437-7772
Keywords:
Stage III non-small cell lung cancer
;
CDDP
;
VP-16
;
Conventional radiotherapy
;
Concurrent chemoand radiotherapy
;
Accelerated proliferation
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Abstract Background. This study was designed to evaluate the feasibility and efficiency of giving cisplatin, etoposide, and OK432 concurrently with conventional radiotherapy (RTx) for patient's with inoperable stage III, based on the TNM classification according to the International Union against Cancer staging system for lung cancer (1987) non-small cell lung cancer (NSCLC). Methods. From January 1992 to December 1994,31 patients with cytologically or histologically confirmed stage III NSCLC were treated with RTx, to a total dose of 56–64 Gy, with concurrent daily oral administration of etoposide (25mg) and cisplatin (20mg) for 5 days during the third or fourth week from the start of RTx. The subcutaneous injection of 1 or 2 KE of OK-432, three times a week, for the duration of radiotherapy also started from the beginning of RTx. Results. The number of eligible patients was 29 (26 men and 3 women). Their mean age was 66 years (range, 55–77 years). Six patients had an Eastern Cooperative Oncology Group performance status (PS) of 0; 15, 1; 8; 2. Three were stage IIIA, and 26, stage ITIB. Histologically, 2 had adenocarcinoma, 23, squamous cell carcinoma, and 4, large cell carcinoma. In 27 of the 29 patients, the RTx schedule was completed. There were no treatment-related deaths. Grade 4 toxicity (according to World Health Organisation criteria) leukopenia (700/μl was observed in 1 patient. The response rate was 79% and the median survival was 17 months. Survival rates at 1, 2 and 3 years were 62%, 31%, and 21%, respectively. The local failure rate was 51%. Conclusion. The combination of cisplatin, etoposide, and K-432, given concurrently with conventional RTx is feasible and effective for inoperable stage III NSCLC.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00539214
Permalink
